Improved survival of children and adolescents with classical Hodgkin lymphoma treated on a harmonised protocol in South Africa.
GICC
Hodgkin lymphoma
South Africa
adolescent
child
harmonisation
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
revised:
11
09
2023
received:
12
05
2023
accepted:
25
09
2023
medline:
24
11
2023
pubmed:
10
10
2023
entrez:
10
10
2023
Statut:
ppublish
Résumé
Historic South African 5-year overall survival (OS) rates for Hodgkin lymphoma (HL) from 2000 to 2010 were 46% and 84% for human immunodeficiency virus (HIV)-positive and HIV-negative children, respectively. We investigated whether a harmonised treatment protocol using risk stratification and response-adapted therapy could increase the OS of childhood and adolescent HL. Seventeen units prospectively enrolled patients less than 18 years, newly diagnosed with classical HL onto a risk-stratified, response-adapted treatment protocol from July 2016 to December 2022. Low- and intermediate-risk patients received four and six courses of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD), respectively. High-risk patients received two courses of ABVD, followed by four courses of cyclophosphamide, vincristine, prednisone, and dacarbazine (COPDac). Those with a slow early response and bulky disease received consolidation radiotherapy. HIV-positive patients could receive granulocyte colony-stimulating factor and less intensive therapy if stratified as high risk, at the treating clinician's discretion. Kaplan-Meier survival analysis was performed to determine 2-year OS and Cox regression to elucidate prognostic factors. The cohort comprised 132 patients (19 HIV-positive, 113 HIV-negative), median age of 9.7 years, with a median follow-up of 2.2 years. Risk grouping comprised nine (7%) low risk, 36 (27%) intermediate risk and 87 (66%) high risk, with 71 (54%) rapid early responders and 45 (34%) slow early responders, and 16 (12%) undocumented. Two-year OS was 100% for low-risk, 93% for intermediate-risk, and 91% for high-risk patients. OS for HIV-negative (93%) and HIV-positive (89%) patients were similar (p = .53). Absolute lymphocyte count greater than 0.6 × 10 In the first South African harmonised HL treatment protocol, risk stratification correlated with prognosis. Two-year OS of HIV-positive and HIV-negative patients improved since 2010, partially ascribed to standardised treatment and increased supportive care. This improved survival strengthens the harmonisation movement and gives hope that South Africa will achieve the WHO Global Initiative for Childhood Cancer goals.
Sections du résumé
BACKGROUND
BACKGROUND
Historic South African 5-year overall survival (OS) rates for Hodgkin lymphoma (HL) from 2000 to 2010 were 46% and 84% for human immunodeficiency virus (HIV)-positive and HIV-negative children, respectively. We investigated whether a harmonised treatment protocol using risk stratification and response-adapted therapy could increase the OS of childhood and adolescent HL.
METHODS
METHODS
Seventeen units prospectively enrolled patients less than 18 years, newly diagnosed with classical HL onto a risk-stratified, response-adapted treatment protocol from July 2016 to December 2022. Low- and intermediate-risk patients received four and six courses of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD), respectively. High-risk patients received two courses of ABVD, followed by four courses of cyclophosphamide, vincristine, prednisone, and dacarbazine (COPDac). Those with a slow early response and bulky disease received consolidation radiotherapy. HIV-positive patients could receive granulocyte colony-stimulating factor and less intensive therapy if stratified as high risk, at the treating clinician's discretion. Kaplan-Meier survival analysis was performed to determine 2-year OS and Cox regression to elucidate prognostic factors.
RESULTS
RESULTS
The cohort comprised 132 patients (19 HIV-positive, 113 HIV-negative), median age of 9.7 years, with a median follow-up of 2.2 years. Risk grouping comprised nine (7%) low risk, 36 (27%) intermediate risk and 87 (66%) high risk, with 71 (54%) rapid early responders and 45 (34%) slow early responders, and 16 (12%) undocumented. Two-year OS was 100% for low-risk, 93% for intermediate-risk, and 91% for high-risk patients. OS for HIV-negative (93%) and HIV-positive (89%) patients were similar (p = .53). Absolute lymphocyte count greater than 0.6 × 10
CONCLUSION
CONCLUSIONS
In the first South African harmonised HL treatment protocol, risk stratification correlated with prognosis. Two-year OS of HIV-positive and HIV-negative patients improved since 2010, partially ascribed to standardised treatment and increased supportive care. This improved survival strengthens the harmonisation movement and gives hope that South Africa will achieve the WHO Global Initiative for Childhood Cancer goals.
Substances chimiques
Dacarbazine
7GR28W0FJI
Vinblastine
5V9KLZ54CY
Bleomycin
11056-06-7
Doxorubicin
80168379AG
Prednisone
VB0R961HZT
Vincristine
5J49Q6B70F
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30712Subventions
Organisme : Carnegie Corporation Research Funding
Organisme : Wits Faculty Research Committee
Organisme : Crowdfunding
Organisme : Doit4Charity
Organisme : Ride Joburg Cycle Race
Informations de copyright
© 2023 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Références
Mechita NB, Cherkaoui S, Abousselham L, et al. Implementing the WHO Global Initiative for Childhood Cancer in Morocco: survival study for the six indexed childhood cancers. Pediatr Blood Cancer. 2022;69(10):e29788. doi:10.1002/pbc.29788
Soliman RM, Elhaddad A, Oke J, et al. Temporal trends in childhood cancer survival in Egypt, 2007 to 2017: a large retrospective study of 14 808 children with cancer from the Children's Cancer Hospital Egypt. Int J Cancer. 2020;148:1562-1574. doi:10.1002/ijc.33321
Mauz-Körholz C, Metzger ML, Kelly KM, et al. Pediatric Hodgkin lymphoma. J Clin Oncol. 2015;33(27):2975-2985. doi:10.1200/JCO.2014.59.4853
World Health Organization. CureAll Framework: WHO global initiative for childhood cancer: increasing access, advancing quality, saving lives. World Health Organization; 2021. Accessed August 12, 2022. https://apps.who.int/iris/handle/10665/347370
Geel JA, Chirwa TC, Rowe B, et al. Treatment outcomes of children with Hodgkin lymphoma between 2000 and 2010: first report by the South African Children's Cancer Study Group. Pediatr Blood Cancer. 2017;64(10):e26536. doi:10.1002/pbc.26536
Beringer N, Bennett KG, Poole JE, Geel JA. Determinants of survival in children with cancer in Johannesburg, South Africa. S Afr J Oncol. 2021;5:a189. doi:10.4102/sajo.v5i0.189
Stones DK, De Bruin GP, Esterhuizen T, Stefan DC. Childhood cancer survival rates in two South African units. S Afr Med J. 2014;104(7):502-504.
Uniform Patient Fee Schedule-National Department of Health. National Department of Health. Accessed February 2, 2023. https://www.health.gov.za/uniform-patient-fee-schedule/
Geel J, Hendricks M, Goga Y, et al. SACCSG HL-2018. Barriers and enablers of a harmonized treatment protocol for childhood and adolescent Hodgkin lymphoma in South Africa. Pediatr Hematol Oncol. 2023;40(03):300-313. doi:10.1080/08880018.2022.2162651
Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol. 2015;4(1):5. doi:10.3978/j.issn.2304-3865.2014.11.03
Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma. 2009;50(8):1257-1260. doi:10.1080/10428190903040048
Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi:10.1016/j.jbi.2019.103208
Schwartz CL, Constine LS, Kelly KM, et al. Childhood Hodgkin International Prognostic Score (CHIPS) predicts event-free survival in Hodgkin lymphoma : a report from the Children's Oncology Group. Pediatr Blood Cancer. 2017;64(4):e26278. doi:10.1002/pbc.26278
Geel JA, Eyal KC, Hendricks MG, et al. Prognostic factors affecting survival in children and adolescents with HIV and Hodgkin lymphoma in South Africa. Leuk Lymphoma. 2020;62(12):2854-2863. doi:10.1080/10428194.2020.1852472
Children (0-14) living with HIV-South Africa | Data. World Bank. Accessed February 11, 2023. https://data.worldbank.org/indicator/SH.HIV.0014?locations=ZA
Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet North Am Ed. 2004;363(9405):263-270. doi:10.1016/S0140-6736(03)15383-4
Daw S, Wynn R, Wallace H. Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents: review. Br J Haematol. 2011;152(3):249-260. doi:10.1111/j.1365-2141.2010.08455.x
Mehrvar A, Tashvighi M, Nourian M, et al. Childhood Hodgkin lymphoma in Iran; survival and outcome. Pediatr Hematol Oncol J. 2020;5(3):100-105. doi:10.1016/j.phoj.2020.06.008
Adams HJA, Kwee TC. Systematic review on the value of end-of-treatment FDG-PET in improving overall survival of lymphoma patients. Ann Hematol. 2020;99(1):1-5. doi:10.1007/s00277-019-03881-x
Diagne Akonde FB, Togo B, Moreira C, et al. Treatment of childhood Hodgkin lymphoma in sub-Saharan Africa: a report from the French-African Paediatric Oncology Group (GFAOP). S Afr J Child Health. 2020;14(3):155-160. doi:10.7196/SAJCH.2020.v14i3.01723
Hines-Thomas MR, Howard SC, Hudson MM, et al. Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma. Haematologica. 2010;95(10):1691-1696. doi:10.3324/haematol.2010.025072